Clinical consequences of resistant Candida infections in intensive care.

Clinical consequences of resistant Candida infections in intensive care.

Item
http://www.wikidata.org/entity/Q36339083
Protease expression by microorganisms and its relevance to crucial physiological/pathological eventsHIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos SantosDetermination of antifungal susceptibility patterns among the clinical isolates of Candida speciesIntensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational studyIn Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs.Nosocomial candidiasis in Rio de Janeiro State: Distribution and fluconazole susceptibility profile.Differential activities of three families of specific beta(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast
P2860

Clinical consequences of resistant Candida infections in intensive care.

Item
http://www.wikidata.org/entity/Q36339083
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Clinical consequences of resistant Candida infections in intensive care.
@ast
Clinical consequences of resistant Candida infections in intensive care.
@en
type
label
Clinical consequences of resistant Candida infections in intensive care.
@ast
Clinical consequences of resistant Candida infections in intensive care.
@en
prefLabel
Clinical consequences of resistant Candida infections in intensive care.
@ast
Clinical consequences of resistant Candida infections in intensive care.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Clinical consequences of resistant Candida infections in intensive care.
@en
P2093
P304
P31
P356
10.1016/J.IJANTIMICAG.2005.11.002
P433
P478
P577
P698